From
To
Blood donor at donation with red bouncy ball holding in hand.
MONDAY, Sept. 8, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved expanded use of Vonvendi (von Willebrand factor [recombinant]) for routine prophylactic use in adults with all types of the blood-clotting disorder von Willebrand disease (VWD), as well as for on-demand treatment of bleeding episodes and perioperative use in children with VWD.
Featured Top Story
Jenna Beasley of Eureka was one of 10 candidates from the St. Louis area selected for the Leukemia & Lymphoma Society’s Visionaries of the…